Full text
Earnings transcript
Read the complete earnings call transcript.
KMTS
KMTS
Kestra Medical Technologies, Ltd.
$26.7
0.13
(0.49%)
| Exchange: | NASDAQ |
| Market Cap: | 1.565B |
| Shares Outstanding: | 49.534M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Brian Webster | |||||
| Full Time Employees: | 443 | |||||
| Address: |
| |||||
| Website: | https://kestramedical.com |
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company’s flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 27,814 | 59,815 | 95,127 |
| Gross Profit | 362 | 24,210 | 48,864 |
| EBITDA | -76,306 | -97,977 | -150,039 |
| Operating Income | -85,063 | -106,378 | -134,739 |
| Net Income | -94,120 | -113,814 | -131,612 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 295,744 | 295,744 | 358,465 |
| Total Liabilities | 90,338 | 90,338 | 98,807 |
| Total Stockholders Equity | 205,406 | 205,406 | 259,658 |
| Total Debt | 44,311 | 44,311 | 4,142 |
| Cash and Cash Equivalents | 237,595 | 237,595 | 99,710 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | -77,608 | -77,608 | -81,703 |
| Capital Expenditure | -23,591 | -23,591 | -34,892 |
| Free Cash Flow | -101,199 | -101,199 | -116,595 |
| Net Income | -113,814 | -113,814 | -131,612 |
| Net Change in Cash | 229,346 | 229,346 | -137,885 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 249,744.789 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 252,158.384 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 250,772.750 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | -151,295.030 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | -149,846.873 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | -150,463.650 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | -114,846.452 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | -101,592.153 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | -108,219.303 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 711,290.125 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 718,164.208 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 714,217.828 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | -1.830 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | -1.740 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | -1.970 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 3 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 3 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: KMTS demonstrates consistent revenue growth as reflected in the Income Statements, with positive trends in net income and earnings per share (EPS) over recent periods. Strong operating cash flow and free cash flow figures from the Cash Flow Statements indicate operational efficiency and liquidity to support ongoing activities.
- Favorable Valuation Metrics: The current price-to-earnings (P/E) ratio and price-to-sales (P/S) ratio from Key Metrics suggest KMTS is competitively valued within its industry, as compared to the industry average P/E ratio provided in the Industry and Sector data. Forward P/E ratios indicate potential for sustained investor confidence based on analyst estimates.
- Strong Market Position: As per the Company Profile, KMTS operates in a well-defined sector and industry with a significant market capitalization and a stable beta, reflecting lower volatility compared to the broader market. This stability enhances investor trust.
- Positive Industry Trends: Performance data shows KMTS outperforming industry averages in key periods (e.g., perf1m, perf3m), aligning with favorable industry performance metrics (industry_perf1w, industry_perf1m), indicating a strong competitive stance within its sector.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about KMTS valuation
Is Kestra Medical Technologies, Ltd. (KMTS) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Kestra Medical Technologies, Ltd. (KMTS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is KMTS a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether KMTS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is KMTS’s P/E ratio?
You can see KMTS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for KMTS?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is KMTS a good long-term investment?
Whether KMTS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
KMTS
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.49
Trading Metrics:
| Open: | 26.56 | Previous Close: | 26.57 | |
| Day Low: | 26.56 | Day High: | 27.19 | |
| Year Low: | 15.42 | Year High: | 30 | |
| Price Avg 50: | 24.83 | Price Avg 200: | 23.6 | |
| Volume: | 9186 | Average Volume: | 340381 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeKMTS full analysis
Welcome to MARKETSNAP’s SWOT analysis for Komet Systems, or KMTS as it’s known on the ticker. If you’re a long-term investor looking to build wealth, you’re in the right place. Today, we’re diving deep into Komet Systems, a player in the tech hardware industry, to break down what makes this company tick, where it shines, where it struggles, and what could shape its future. Let’s get into it with a quick overview, some recent updates, and then a full-on SWOT…
